Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with or without ipilimumab for melanoma brain metastases
ACTRN12614001315606Phase 2Active, not recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in melanoma and brain metastases (3 cohorts), sponsored by Melanoma Institute Australia. Primary endpoint: Intracranial objective response rate. Started Oct 2014; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on ACTRN12614001315606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001315606.